“We look forward to sharing the topline data readout for SURMOUNT-5 later this year.”

In context

“leased to share that we expect U.S. regulatory action for tirzepatide in adults with obesity and obstructive sleep apnea yet this year. And that we will submit for U.S. approval for tirzepatide in adults with obesity and heart failure with Preserved Ejection Fraction before the end of this year. Another avenue to advance patient care is the maintenance of body weight reductions. We are conducting two Phase 3b weight loss maintenance trials. The first is SURMOUNT-MAINTAIN, which compares either tirzepatide 5 milligrams or tirzepatide maximum tolerated dose to placebo. The second is ATTAIN-MAINTAIN, which evaluates our oral GLP-1 orforglipron versus placebo after tirzepatide or semaglutide in participants who completed SURMOUNT-5, the 3b head-to-head study of tirzepatide versus semaglutide. We look forward to sharing the topline data readout for SURMOUNT-5 later this year. Next, in oncology. The Phase 3 EMBER-3 study evaluating our oral SERD, imlunestrant, in patients with second-line ER positive HER2 negative metastatic breast cancer was positive. The study evaluated three-arms, imlunestrant as a monotherapy, investigator's choice of endocrine therapy monotherapy, and imlunestrant in combination with abemaciclib. Based on the results from this trial, we expect to submit an NDA to the FDA by year-end, and we look forward to sharing detailed results at an upcoming medical meeting. The Phase 3 portion of the olomorasib first-line KRAS G12C lung cancer study is now underway. The first Phase 3 trial for this class of medicines in newly diagnosed locally advanced or metastatic lung cancer regardless of PD-L1 expression. This comes after recently defining the dos”